Q&A: BioNTech co-founders discuss immuno-oncology efforts, Bristol Myers dealnews2025-11-13T15:00:44+00:00November 13th, 2025|Endpoints News|
Merck KGaA still in tariff talks with the White House, weeks after deal was announced news2025-11-13T14:29:36+00:00November 13th, 2025|Endpoints News|
Mental health companies, once wary of AI, are building chatbotsnews2025-11-13T14:00:56+00:00November 13th, 2025|Endpoints News|
Gate Bioscience captures another $65M with new take on protein degradationnews2025-11-13T13:00:51+00:00November 13th, 2025|Endpoints News|
Q&A: Bausch + Lomb CEO Brent Saunders on turnaround, AI, TrumpRxnews2025-11-13T12:00:49+00:00November 13th, 2025|Endpoints News|
Korro Bio abandons lead genetic disease drug candidate after disappointing datanews2025-11-13T11:56:02+00:00November 13th, 2025|Endpoints News|
Zealand pauses development of GLP-1/GLP-2 obesity candidatenews2025-11-13T11:50:28+00:00November 13th, 2025|Endpoints News|
Novartis says Phase 3 data prove new antimalarial could address resistancenews2025-11-12T22:00:50+00:00November 12th, 2025|Endpoints News|
FDA announces new regulatory pathway for personalized rare disease therapiesnews2025-11-12T22:00:19+00:00November 12th, 2025|Endpoints News|
Pazdur vs. Prasad: Can the CDER-CBER dynamic change under new leadership?news2025-11-12T20:37:57+00:00November 12th, 2025|Endpoints News|
